Dengue fever, a mosquito-borne viral illness, is experiencing a dramatic global surge, with reported cases rising sharply in 2024 and 2025. The World Health Organization (WHO) has noted record-breaking transmission in regions including the Americas, where over 6.5 million cases were reported in 2023 alone. The primary vectors, Aedes aegypti and Aedes albopictus mosquitoes, are expanding their range due to climate change, increased urbanization, and international travel, bringing the disease to new populations.
The development of effective vaccines faces significant scientific challenges. Dengue is caused by four distinct but related virus serotypes. A person's second infection with a different serotype often leads to more severe disease due to a phenomenon known as antibody-dependent enhancement (ADE). This complexity makes creating a vaccine that protects against all four serotypes without increasing the risk of severe illness exceptionally difficult.
Currently, a few vaccines are available with specific limitations. The Qdenga vaccine (TAK-003) is approved for use in the European Union, the UK, and several endemic countries for individuals aged 4 and above, regardless of prior dengue exposure. Another vaccine, Dengvaxia (CYD-TDV), is recommended by the WHO only for individuals with a confirmed prior dengue infection, due to the risk of severe disease in those who are dengue-naïve. Research into next-generation vaccines and novel control methods, including Wolbachia-infected mosquitoes, continues.
Public health efforts remain focused on mosquito control and community awareness as primary defenses. The WHO emphasizes the need for integrated surveillance, vector control, and clinical management to combat the escalating threat, which places a heavy burden on healthcare systems in endemic countries.
